Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma (NCT05673083)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this pilot study is to evaluate the impact of All4Cure enrollment on patients with multiple myeloma. The main question it aims to answer are: • Does All4Cure effect patient activation as assessed by the PAM-13 survey? Participants will be asked to: * fill out quarterly PAM-13 surveys through the All4Cure website to assess patient activation. * fill out monthly Patient Reported Outcome (PRO) surveys through the All4Cure website. * fill out a baseline and exit All4Cure surveys through the All4Cure website to assess patient perceptions of All4Cure at the beginning and the end of the study.
Who can join: Review the eligibility criteria below.
Location: Highlands Oncology Group — Fayetteville, Arkansas
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Highlands Oncology Group — Fayetteville, Arkansas
- Cancer Specialists of North Florida — Jacksonville, Florida
- Misson Cancer + Blood — Des Moines, Iowa
- Hematology-Oncology Associates of Central New York — East Syracuse, New York
- Oklahoma Cancer Specialists and Research Institute — Tulsa, Oklahoma
- Oncology Consultants — Houston, Texas
- Northwest Medical Specialties PLLC — Tacoma, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma in Relapse
- Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma — Denver, Colorado
- Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) — Gilbert, Arizona
- Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma — Aurora, Colorado
- A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma — West Hollywood, California
- A Trial of Selinexor, Ruxolitinib and Methylprednisolone — West Hollywood, California
Explore by condition: All Multiple Myeloma in Relapse clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.